Primary Human Pancreatic Cancer Cells Cultivation in Microfluidic Hydrogel Microcapsules for Drug Evaluation
Advanced Science · 2023
DOI: 10.1002/advs.202206004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Taiyu Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Institute of Translational Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical Scho…. Hauptthemen laut MEDLINE: Microfluidics, Pancreatic Neoplasms. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Shenzhen Fundamental Research Program, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
Chemotherapy is an essential postoperative treatment for pancreatic cancer, while due to the lack of effective drug evaluation platforms, the therapeutic outcomes are hampered by tumor heterogeneity among individuals. Here, a novel microfluidic encapsulated and integrated primary pancreatic cancer cells platform is proposed for biomimetic tumor 3D cultivation and clinical drug evaluation. These primary cells are encapsulated into hydrogel microcapsules of carboxymethyl cellulose cores and alginate shells based on a microfluidic electrospray technique. Benefiting from the good monodispersity, stability, and precise dimensional controllability of the technology, the encapsulated cells can proliferate rapidly and spontaneously form 3D tumor spheroids with highly uniform size and good cell viability. By integrating these encapsulated tumor spheroids into a microfluidic chip with concentration gradient channels and culture chambers, dynamic and high‐throughput drug evaluation of different chemotherapy regimens could be realized. It is demonstrated that different patient‐derived tumor spheroids show different drug sensitivity on‐chip, which is significantly consistent with the clinical follow‐up study after the operation. The results demonstrate that the microfluidic encapsulated and integrated tumor spheroids platform has great application potential in clinical drug evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Institute of Translational Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210002, China.
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, China.
- Zhongshan-Xuhui Hospital and the Shanghai Key Laboratory of Medical Epigenetics the International Colaboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Institutes of Biomedical Science…
- Chemistry and Biomedicine Innovation Center, Nanjing University, Nanjing, 210023, China.
ORCID-Profile: Taiyu Song, Yuanjin Zhao
Förderung
- National Key Research and Development Program of China
- Shenzhen Fundamental Research Program
- Guangdong Basic and Applied Basic Research Foundation
Zitieren
APA
Song, T., Zhang, H., Luo, Z., Shang, L., & Zhao, Y. (2023). Primary Human Pancreatic Cancer Cells Cultivation in Microfluidic Hydrogel Microcapsules for Drug Evaluation. Advanced Science. https://doi.org/10.1002/advs.202206004
Vancouver
Song T, Zhang H, Luo Z, Shang L, Zhao Y. Primary Human Pancreatic Cancer Cells Cultivation in Microfluidic Hydrogel Microcapsules for Drug Evaluation. Advanced Science. 2023. doi:10.1002/advs.202206004
BibTeX
@article{Song2023,
author = {Song, Taiyu and Zhang, Hui and Luo, Zhiqiang and Shang, Luoran and Zhao, Yuanjin},
title = {Primary Human Pancreatic Cancer Cells Cultivation in Microfluidic Hydrogel Microcapsules for Drug Evaluation},
journal = {Advanced Science},
year = {2023},
doi = {10.1002/advs.202206004}
}
EUVIMED